GlassScriptPhysician profile
David M Rizzo
NPI 1447267208
$2,228.21
in general payments reported to CMS, 2019-2025
28 companies · $95.74 in 2025
The $95.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.73 · 2020: $370 · 2021: $1,036 · 2022: $389 · 2023: $91.22 · 2024: $187 · 2025: $95.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $581.64 | 2019-2025 | |
| Pfizer INC. | $251.60 | 2019-2023 | |
| Abbvie INC. | $209.60 | 2021-2022 | |
| Exact Sciences Corporation | $116.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $112.62 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.41 | 2020-2021 | |
| Glaxosmithkline, LLC. | $99.53 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $95.12 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $66.52 | 2022 | |
| Jazz Pharmaceuticals INC. | $54.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $47.87 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $42.61 | 2021 | |
| Vanda Pharmaceuticals INC. | $41.30 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.09 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.29 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36.99 | 2024 | |
| Amgen INC. | $33.63 | 2021 | |
| Merck Sharp & Dohme LLC | $33.43 | 2020 | |
| Nestle Healthcare Nutrition INC. | $31.61 | 2021 | |
| Allergan, INC. | $27.14 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $23.72 | 2021 | |
| Novo Nordisk INC | $22.70 | 2021 | |
| Scilex Pharmaceuticals INC. | $21.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.28 | 2021 | |
| Horizon Therapeutics Plc | $19.49 | 2020 | |
| Kvk-Tech, INC. | $19.07 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $18.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rizzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.